VTRS NASDAQ
Viatris Inc.
1W: +0.4%
1M: +2.5%
3M: +5.0%
YTD: +50.2%
1Y: +83.0%
3Y: +123.1%
5Y: +66.4%
$18.72
+0.43 (+2.35%)
Weekly Expected Move ±4.1%
$17
$17
$18
$19
$19
Credit Risk of going bust: lower than 54% of companies Debt: 38.8% of company value Bonds: $302.8M held by 306 funds, 161 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.77 (down 96%), Viatris Inc. would be worth roughly what it owes.
Total debt $13.63B against a stock market value of $21.50B.
Distance to default 5.57 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $7.55B (short-term plus half of long-term), stock volatility 32.4%; Altman Z 1.15. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.77 (down 96%), Viatris Inc. would be worth roughly what it owes.
Total debt $13.63B against a stock market value of $21.50B.
Distance to default 5.57 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $7.55B (short-term plus half of long-term), stock volatility 32.4%; Altman Z 1.15. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
19 relationships17
As Filer
counterparties named
2
As Counterparty
mentioned by others
5
Rel. Types
2021-07-01
Earliest Filing
2024-10-16
Latest Filing
partner: 5
acquirer: 4
investor: 4
target: 3
customer: 1
Counterparties (Filed by VTRS)
17 relationshipsCompanies named in VTRS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Cooper Consumer Health SAS | — | customer | Acquirer of Viatris' over-the-counter products business | 2024-07-03 | View |
| Cooper Consumer Health IT S.r.l. | — | partner | — | 2024-07-03 | View |
| Cooper Consumer Health SAS | — | acquirer | French corporation making a binding offer to purchase Viatris' over-the-counter products business | 2024-01-30 | View |
| Cooper Consumer Health IT S.r.l. | — | acquirer | Affiliate of Cooper Consumer Health SAS involved in the Transaction Agreement | 2024-01-30 | View |
| Cooper Consumer Health SAS | — | acquirer | Buyer Parent making a binding offer to purchase Viatris' over-the-counter products business | 2023-10-02 | View |
| Biocon Biologics Limited | — | acquirer | Buyer in the transaction agreement | 2022-11-29 | View |
| Viatris Inc. | VTRS | target | Seller Parent in the transaction agreement | 2022-11-29 | View |
| Mylan Ireland Limited | — | target | Subsidiary of Seller Parent transferring biosimilars trade | 2022-11-29 | View |
| Biosimilar Collaborations Ireland Limited | — | target | Irish Acquired Company receiving biosimilars trade | 2022-11-29 | View |
| Serum | — | investor | Counterparty to Equity Financing Letter | 2022-11-29 | View |
| Biocon Pharma Limited | — | investor | BPL, counterparty to Equity Financing Letter Amendment | 2022-11-29 | View |
| Biocon Biologics Limited | — | partner | Viatris contributes its biosimilars portfolio to Biocon Biologics in exchange for cash and a convertible preferred equit | 2022-02-28 | View |
| Biocon Limited | — | investor | Committed to provide approximately $500 million in equity financing for the transaction. | 2022-02-28 | View |
| Serum Institute Life Sciences Private Limited | — | investor | Committed to provide approximately $300 million in equity financing for the transaction. | 2022-02-28 | View |
| Mylan Inc. | — | partner | Guarantor for both credit agreements | 2021-07-01 | View |
| Utah Acquisition Sub Inc. | — | partner | Guarantor for both credit agreements | 2021-07-01 | View |
| Mylan II B.V. | — | partner | Guarantor for both credit agreements | 2021-07-01 | View |
Mentioned As Counterparty
2 mentionsOther companies that named VTRS in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| LXRX LEXICON PHARMACEUTICALS, INC. | licensee | Exclusive license agreement for development and commercialization of sotagliflozin outside the US and Europe. | 2024-10-16 | View |
| IRD Ocuphire Pharma, Inc. | partner | Agreed to procure the commercialization of the Products in the Territory for each indication that receives regulatory ap | 2022-11-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-08 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-08-06 | Earnings Release; Other Events; Exhibits | View | |
| 2026-07-01 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-06-18 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-06-15 | Other Events; Exhibits | View | |
| 2026-05-15 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Other Events; Exhibits | View | |
| 2026-05-04 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; Ot | View | |
| 2026-02-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-12-08 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-05 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-12-05 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-10-24 | Amendments to Articles of Incorporation or Bylaws; Shareholder Nominations; Other Events; Financial | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-05 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-05 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR